SCHEMBL2128073

SCHEMBL2128073

COc1c(C=Cc2ccccc2C(=O)O)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.61
ERN1 O75460 1/20 0.39
GRIK1 P39086 1/20 0.38
GRIA1 P42261 1/20 0.38
GRIA2 P42262 1/20 0.38
GRIA3 P42263 1/20 0.38
GRIA4 P48058 1/20 0.38
GRIK2 Q13002 1/20 0.38
GRIK3 Q13003 1/20 0.38
TNFRSF1A P19438 1/20 0.38
NAPRT Q6XQN6 1/20 0.38
CYP1A1 P04798 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2D6 P10635 2/20 0.35
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
KDM4E B2RXH2 2/20 0.33
EGFR P00533 1/20 0.33
ERBB2 P04626 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1542955 1.00 CYP3A4 (0.61) CYP3A4ERN1GRIK1GRIA1GRIA2
SCHEMBL1543043 0.92 CYP3A4 (0.61) CYP3A4ERN1TNFRSF1ACYP1A1CYP1A2
SCHEMBL1543045 0.92 CYP3A4 (0.61) CYP3A4ERN1TNFRSF1ACYP1A1CYP1A2
SCHEMBL1542678 0.91 CYP3A4 (0.62) CYP3A4ERN1TNFRSF1ACYP1A1CYP1A2
SCHEMBL2128341 0.91 CYP3A4 (0.62) CYP3A4ERN1TNFRSF1ACYP1A1CYP1A2
SCHEMBL1764330 0.87 CYP3A4 (0.74) CYP3A4TNFRSF1ACYP1A1CYP1A2EGFR
SCHEMBL1764331 0.87 CYP3A4 (0.74) CYP3A4TNFRSF1ACYP1A1CYP1A2EGFR
SCHEMBL1542386 0.85 CYP3A4 (0.64) CYP3A4ERN1TNFRSF1ACYP1A1CYP1A2
SCHEMBL1542383 0.85 CYP3A4 (0.64) CYP3A4ERN1TNFRSF1ACYP1A1CYP1A2
SCHEMBL2127426 0.84 CYP3A4 (0.76) CYP3A4FABP4CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US disclosed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885ERN1 140/4885GRIK1 4795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.